Published in Antimicrob Agents Chemother on June 01, 1987
Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother (1989) 1.40
Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1988) 1.40
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1989) 1.15
In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrob Agents Chemother (1990) 0.92
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
In vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax (1990) 0.81
Approaches to antiviral drug development. Yale J Biol Med (1989) 0.78
The synthesis of branched-chain 3'-C-cyanomethyl-2',3'-dideoxy sugar nucleosides of adenine as potential inhibitors of the human immunodeficiency virus. Nucleic Acids Res (1989) 0.75
Pathogenesis of human immunodeficiency virus infection and prospects for control. Yale J Biol Med (1988) 0.75
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A (1986) 5.18
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet (1987) 2.30
Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet (1984) 2.12
Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83
Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother (1986) 1.72
Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun (1987) 1.67
Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother (1986) 1.66
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51
Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A (1986) 1.43
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine. Biochem Biophys Res Commun (1986) 1.19
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int J Cancer (1986) 1.10
In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin. J Infect Dis (1986) 1.01
Recombinant human interferon gamma suppresses HTLV-III replication in vitro. Int J Cancer (1986) 1.00
Prospects for the prevention and therapy of infections with the human immunodeficiency virus. Rev Infect Dis (1987) 0.85
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature (1988) 7.00
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet (1989) 5.09
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci U S A (1989) 4.21
Macrophages and age-dependent resistance to Herpes simplex virus in mice. J Immunol (1970) 4.15
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res (1991) 3.56
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice. J Immunol (1970) 3.49
Pathogenesis of infection with human immunodeficiency virus. N Engl J Med (1987) 3.45
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science (1988) 3.08
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature (1993) 2.73
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res (1989) 2.54
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (1980) 2.41
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol (1986) 2.37
Immunopathology of lymphocytic choriomeningitis viurs infection of newborn mice. Antithymocyte serum effects on glomerulonephritis and wasting disease. J Exp Med (1968) 2.31
Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis (1977) 2.30
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Report of the Committee on the Genetic Constitution of Chromosomes 20, 21, and 22. Cytogenet Cell Genet (1985) 2.18
Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med (1988) 2.17
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res (1989) 2.04
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol (1977) 2.01
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
Assignment of the human pro alpha 2(I) collagen structural gene (COLIA2) to chromosome 7 by molecular hybridization. Am J Hum Genet (1982) 1.98
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet (1986) 1.96
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Effects of anti-lymphoid sera on viral infections. Lancet (1968) 1.87
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Enzymatic repair of DNA, 1. Purification of two enzymes involved in the excision of thymine dimers from ultraviolet-irradiated DNA. Proc Natl Acad Sci U S A (1969) 1.85
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med (1985) 1.83
Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis (1981) 1.81
Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis (1988) 1.81
Human type I procollagen genes are located on different chromosomes. Proc Natl Acad Sci U S A (1982) 1.78
Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med (1985) 1.78
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
Infection of human endothelial cells by human T-lymphotropic virus type I. Proc Natl Acad Sci U S A (1984) 1.73
International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol (1979) 1.71
Effects of anti-thymocyte serum on lymphocytic choriomeningitis (LCM) virus infection in mice. Proc Soc Exp Biol Med (1967) 1.71
Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature (1992) 1.70
Replication of herpes simplex virus and cytomegalovirus in human leukocytes. J Immunol (1978) 1.69
Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol (1983) 1.67
Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord (1991) 1.65
The isolation of a human Ig V lambda gene from a recombinant library of chromosome 22 and estimation of its copy number. Nucleic Acids Res (1984) 1.61
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol (1993) 1.61
Antibody to lymphadenopathy-associated virus in AIDS. N Engl J Med (1985) 1.59
Isolation patterns of the human immunodeficiency virus from cervical secretions during the menstrual cycle of women at risk for the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.59
Methylation of the viral genome in an in vitro model of herpes simplex virus latency. Proc Natl Acad Sci U S A (1982) 1.56
Leukemia virus activation in chronic allogeneic disease. Proc Natl Acad Sci U S A (1970) 1.55
Dystrophin gene transcribed from different promoters in neuronal and glial cells. Nature (1990) 1.54
Quantitative estimation of minor mRNAs by cDNA-polymerase chain reaction. Application to dystrophin mRNA in cultured myogenic and brain cells. Eur J Biochem (1990) 1.52
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51
Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol (1996) 1.51
Infection of the retina by human immunodeficiency virus type I. N Engl J Med (1987) 1.50
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Immune complexes in mice infected neonatally with Moloney leukaemogenic and murine sarcoma viruses. Nature (1969) 1.46
Immune response to herpesvirus antigens in adults with acute cytomegaloviral mononucleosis. J Infect Dis (1979) 1.46